Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.49 |
| ▸ | SCN1A | P35498 | 3/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.48 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HNF4A | P41235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9024484 | 0.89 | LMNA (0.47) | LMNAMEN1KMT2ASMN1; SMN2SCN1A | |
| SCHEMBL9024359 | 0.85 | LMNA (0.44) | LMNAMEN1KMT2ASCN1ASCN2A | |
| SCHEMBL27300818 | 0.83 | PTGDR2 (0.49) | LMNAMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9405743 | 0.83 | LMNA (0.42) | LMNASCN1ASCN2ASCN3AALDH1A1 | |
| SCHEMBL9405741 | 0.83 | LMNA (0.42) | LMNAMEN1KMT2ASMN1; SMN2SCN1A | |
| SCHEMBL11575282 | 0.80 | LMNA (0.50) | LMNAMEN1KMT2ASMN1; SMN2BCAT2 | |
| SCHEMBL26129433 | 0.80 | THRB (0.45) | LMNAMEN1KMT2ASMN1; SMN2BCAT2 | |
| SCHEMBL1301580 | 0.77 | SMN1; SMN2 (0.54) | LMNAMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3420505 | 0.77 | BCAT2 (0.57) | LMNAMEN1KMT2ASMN1; SMN2BCAT2 | |
| SCHEMBL30505632 | 0.77 | BCAT2 (0.57) | LMNAMEN1KMT2ASMN1; SMN2BCAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| EP-1648876-A1 | 5-HT SB 2B /SB RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012263-A1 | 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| EP-0305952-B1 | SUBSTITUTED 2-PHENYL-4-QUINOLINE-CARBOXYLIC ACIDS | AMERICAN CYANAMID COMPANY (US) | 1993-06-02 | — | — | EP | disclosed |
| US-4847381-A | ANTIARTHRITIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0305952-A1 | Substituted 2-phenyl-4-quinoline-carboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | HTR2B, HTR1B, HTR3B | LMNA 3744/4885MEN1 3047/4885KMT2A 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.